Fundraising FoxRenibus Therapeutics
Southlake, US · Founded 2015 · Delaware corporation
Find your way into Renibus Therapeutics
Sign up to see every warm intro you have to Renibus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Renibus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JD
Jamie DonadioExecutiveJamie Donadio is an executive at Renibus Therapeutics with over 20 years of experience in finance and the life sciences industry, including roles across drug development and commercialization in biopharmaceutical companies.
DJ
D. Jeffrey KeyserExecutive
HK
Harpreet KaurChairman of the Board, Chief Executive Officer and President
NB
Nels BergmarkTreasurer
Board
CG
Carlos GuillemBoard director
HR
Henrik RasmussenBoard director
JK
Jocelyn KeyserBoard director
JD
Jennifer D. RasmussenBoard director
DJ
Dale JonesBoard director
Funding
SEC filings, press & company announcements$180.1M disclosed across 5 of 6 rounds · 2016–2023
- Undisclosed amountSeries AFeb 2022Source ↗
▶$110.9MraisedJul 2025 · 59 investors · PharmaceuticalsRule 506(b)
▶$110.9MraisedJul 2025 · 59 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jamie DonadioExecutive Officer
- Bhupinder SinghExecutive Officer, Director
- Carlos GuillemDirector
- D. Jeffrey KeyserExecutive Officer, Director
- Henrik RasmussenDirector
- Offering amount
- $110.9M
- Amount sold
- $110.9M
- Finders' fees
- $148.3K
- Placement agents
- Salem Partners LLC
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.4MraisedAug 2022 · 18 investors · PharmaceuticalsRule 506(b)
▶$23.4MraisedAug 2022 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carlos GuillemDirector
- Jamie DonadioExecutive Officer
- Henrik RasmussenDirector
- D. Jeffrey KeyserExecutive Officer, Director
- Frank StonebanksExecutive Officer, Director
- Bhupinder SinghExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $23.4M
- Sales commissions
- $12K
- Placement agents
- Melior Capital Management GMBH
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$34.6MraisedFeb 2022 · 30 investors · PharmaceuticalsRule 506(b)
▶$34.6MraisedFeb 2022 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Henrik RasmussenDirector
- Bhupinder SinghDirector
- Frank StonebanksExecutive Officer, Director
- D. Jeffrey KeyserExecutive Officer, Director
- Alvaro GuillemDirector
- Offering amount
- $34.6M
- Amount sold
- $34.6M
- Sales commissions
- $116.6K
- Placement agents
- Melior Capital Management GMBH
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.9MraisedMay 2016 · 112 investors · PharmaceuticalsRule 506(b)
▶$10.9MraisedMay 2016 · 112 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jennifer D. RasmussenDirector
- Harpreet KaurExecutive Officer, Director
- Nels BergmarkExecutive Officer
- Carlos GuillemExecutive Officer, Director
- Jocelyn KeyserDirector
- Dale JonesDirector
- Offering amount
- $12.5M
- Amount sold
- $10.9M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$300KraisedFeb 2016 · 4 investors · PharmaceuticalsRule 506(b)
▶$300KraisedFeb 2016 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jocelyn KeyserDirector
- Jennifer D. RasmussenDirector
- Carlos GuillemExecutive Officer, Director
- Harpreet KaurExecutive Officer, Director
- Dale JonesDirector
- Nels BergmarkExecutive Officer
- Offering amount
- $300K
- Amount sold
- $300K
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Renibus Therapeutics raised?
- Renibus Therapeutics has disclosed $180.1M raised across 5 of its 6 known rounds.
- Where is Renibus Therapeutics headquartered?
- Renibus Therapeutics is headquartered in Southlake, US.